Ruiz-Sandoval MC, Reséndiz-Ramírez Y, Villaseñor-Cabrera T, Álvarez-Palazuelos LE, Chiquete E, Ruiz-Sandoval JL

Idioma: Español
Referencias bibliográficas: 26
Paginas: 302-305
Archivo PDF: 265.50 Kb.

RESUMEN

Introducción: La neuropatía motora multifocal con bloqueo de conducción (NMMBC) es una entidad rara de causa autoinmune caracterizada por debilidad asimétrica distal de predominio en extremidades superiores, arreflexia y atrofia muscular. Caso clínico: Hombre de 31 años con NMMBC de inicio en la infancia con alteraciones cognitivas y psico-conductuales evidenciadas desde la adolescencia. Conclusiones: La presencia de anticuerpos anti-gangliósido GM1 explica no sólo el síndrome neuropático, sino también las alteraciones neuropsicológicas, dado que los GM1 existen también a nivel central.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Chronic multifocal demyelinative neuropathy: An unique disorder with persistent conduction block. Neurology 1979; 29: 610-1.

2. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32: 958-64.

3. Traba A, Esteban-García A. Neuropatía motora multifocal. Rev Neurol 2000; 30: 519-25.

4. Parry GJ, Clarke S. Multifocal acquired demyeinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988; 11: 103-7.

5. Parry GJ, Sumner AJ. Multifocal motor neuropathy. Neurol Clin 1992; 10: 671-84.

6. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000; 23: 900-8.

7. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1997; 63: 765-9.

8. Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy. A doble-blind, placebo controlled study. Brain 2001; 124: 145-53.

9. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile- Orazio E. How long is IVIg effective in multifocal motor neuropathy? Neurology 2004; 62: 666-8.

10. Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007; 69: 1680-7.

11. Moroni I, Bugiani M, Ciano C, Bono R, Pareyson D. Childhood-onset multifocal motor neuropathy with conduction blocks. Neurology 2006; 66: 922-4.

12. Wilson CM, Grace GM, Muñoz DG, He BP, Strong MJ. Cognitive impairment in sporadic ALS. A pathologic continuum underlying a multisystem disorder. Neurology 2001; 57: 651-7.

13. Wheaton MW, Salamone AR, Mosnik DM, McDonald RO, Appel SH, Schmolck HI, et al. Cognitive impairment in familial ALS. Neurology 2007; 69; 1411-7.

14. Stewart SB, Ro0bertson KR, Johnson KM, Howard Jr JF. The prevalence of depression in myasthenia gravis. J Clin Neuromusc Dis 2007; 8: 111-5.

15. Paulson HL, Garbern JY, Hoban TF, Krajewski KM, Lewis RA, Fischbeck KH, et al. Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002; 52: 429-34.

16. Sacco S, Totaro R, Bastianello S, Marini C, Carolei A. Brain white matter lesions in an Italian family with Charcot-Marie-Tooth disease. Eur Neurol 2004; 51: 168-71.

17. Amato AA, Barohn RJ. Hereditary neuropathy with liability to pressure palsies: association with central nervous system demyelination. Muscle Nerve 1996; 19: 770-3.

18. Tackenberg B, Möller JC, Rindock H, Bien S, Sommer N, Oertel WH, et al. CNS involvement in hereditary neuropathy with pressure palsies (HNPP). Neurology 2006; 67: 2250-2.

19. Hamner MB. Recurrent psychotic depression associated with GM2 gangliosidosis. Psychosomatics 1998; 39: 446-8.

20. Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 2008; 94: 391-6.

21. Segler-Stahl K, Webster JC, Brunngraber EG. Changes in the concentration and composition of human brain gangliosides with aging. Gerontology 1983; 29: 161-8.

22. Kracun I, Rosner H, Drnovsekv V, Heffer-Lauc M, Cosovic C, Lauc G. Human brain gangliosides in development, aging and disease Int J Dev Biol 1991; 35: 289-95.

23. Brooksbank BW, McGovern J. Gangliosides in the brain in adult Down’s syndrome and Alzheimer’s disease. Mol Chem Neuropathol 1989; 11: 143-56.

24. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002; 41: 7385-90.

25. Yanagisawa K. GM1 ganglioside and the seeding of amyloid in Alzheimer’s disease: endogenous seed for Alzheimer amyloid. Neuroscientist 2005; 11: 250-60.

26. Yanagisawa K. Role of gangliosides in Alzheimer’s disease. Biochim Biophys Acta 2007; 1768: 1943-51.